Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of the parent company between 191 million and 229 million yuan for the year 2025, indicating a year-on-year increase of 13.64 million to 51.85 million yuan, representing a growth rate of 7.69% to 29.23% compared to the previous year [1] Financial Performance - The projected net profit for 2025 is estimated to be between 191 million and 229 million yuan [1] - The expected increase in net profit ranges from 13.64 million to 51.85 million yuan compared to the previous year [1] - The anticipated year-on-year growth rate is between 7.69% and 29.23% [1]

Core Viewpoint - The company, 阳光诺和, expects a net profit attributable to shareholders for the year 2025 to be between 191.05 million and 229.26 million yuan, representing a year-on-year growth of 7.69% to 29.23% [1] - The company anticipates a net profit excluding non-recurring gains and losses to be between 179.70 million and 215.64 million yuan, with a year-on-year growth of 8.84% to 30.61% [1] Group 1: Revenue and Profit Growth - The company has achieved steady growth in revenue and profit, driven by the deep layout of its innovative drug pipeline, realization of value from licensing collaborations, and synergistic support from its integrated service model [1] - The implementation of the "R&D services + pipeline cultivation + new quality industrial chain" strategy has provided solid support for business growth, leading to a steady improvement in the company's profitability [2] Group 2: Innovative Drug Pipeline - The company focuses on the research and development of innovative drugs with global independent intellectual property rights, constructing a pipeline matrix that includes over 20 first-class new drugs targeting major diseases such as cancer and pain [1] - Core pipelines like STC007 and STC008 have successfully entered critical clinical stages, generating stable income through R&D services and laying the foundation for long-term value release [1] Group 3: Licensing Collaborations - Licensing collaborations and revenue sharing have become key drivers of profit growth, with significant income generated from the licensing of pipelines such as STC007 and STC008, contributing to a high-margin revenue source [2] - The continuous optimization of the business structure is facilitated by these licensing agreements, enhancing the overall profitability of the company [2]

Core Insights - The company expects a net profit attributable to shareholders for the year 2025 to be between 191.05 million and 229.26 million yuan, representing a year-on-year growth of 7.69% to 29.23% [1] - The projected net profit after deducting non-recurring gains and losses is estimated to be between 179.70 million and 215.64 million yuan, with a year-on-year increase of 8.84% to 30.61% [1] Group 1 - The company's revenue and profit are showing steady growth, driven by the deep layout of its innovative drug pipeline, realization of value from licensing collaborations, and synergistic support from its integrated service model [1] - The innovative drug pipeline focuses on research and development of drugs with global intellectual property rights, covering cutting-edge areas such as peptides, small nucleic acids, cell and gene therapy, including over 20 first-class new drugs targeting major diseases like cancer and pain [1] - The company efficiently promotes R&D projects through a "preclinical + clinical" integrated service model, supported by a comprehensive quality management system and a clinical cooperation network with over 300 hospitals [1] Group 2 - Licensing collaborations and revenue sharing have become key drivers of profit growth, with significant income generated from the licensing of pipelines such as STC007 and STC008, contributing to a high-margin revenue source [2] - The implementation of the "R&D services + pipeline cultivation + new quality industrial chain" strategy provides solid support for business growth, steadily enhancing the company's profitability [2]

证券代码：688621 证券简称：阳光诺和 公告编号：2026-005 北京阳光诺和药物研究股份有限公司 关于公司诉讼结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一审判决支付金额：湖南恒生制药股份有限公司（以下简称"恒生制药"） 向北京阳光诺和药物研究股份有限公司（以下简称"阳光诺和"或"公司"）支付拖 欠研发费用合计 25.4 万元及相应逾期支付违约金。 是否会对上市公司损益产生负面影响：公司根据审慎性原则按照会计准 则已对恒生制药应收账款和合同资产全额计提了坏账准备，因此该诉讼事项对公 司当期及期后利润不会构成负面影响。截至本公告日，本案尚处于上诉期内，最 终执行情况尚存在不确定性，对公司造成的具体影响需以生效判决的实际执行情 况为准。 一、本次重大诉讼的基本情况 2025 年 8 月 2 日，阳光诺和在上海证券交易所网站（www.sse.com.cn）披露 了《北京阳光诺和药物研究股份有限公司关于公司诉讼事项进展暨提起新诉讼的 公告》（公告编号：2025-061），公司就恒生制药拖欠公 ...

Core Viewpoint - Sunshine Nuohuo (688621) expects a net profit attributable to shareholders of the parent company for the fiscal year 2025 to be between 191 million and 229 million yuan, representing a year-on-year growth of 7.69% to 29.23% [1] Group 1: Financial Performance - The company anticipates a net profit range of 191 million to 229 million yuan for 2025, indicating a positive growth trajectory [1] - The expected growth rate of net profit is between 7.69% and 29.23%, showcasing strong financial performance [1] Group 2: Revenue Sources - The company has generated significant revenue through intellectual property licensing transactions, contributing to high-margin income [1] - The authorized cooperation of pipelines such as STC007 and STC008 has provided considerable revenue, enhancing the company's financial stability [1] Group 3: Strategic Initiatives - The implementation of the "R&D services + pipeline cultivation + new quality industrial chain" strategy has provided a solid foundation for business growth [1] - This strategic approach is driving steady improvements in the company's profitability [1]

证券代码：688621 证券简称：阳光诺和 公告编号：2026-004 北京阳光诺和药物研究股份有限公司 自愿披露 2025 年年度业绩预告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况 经北京阳光诺和药物研究股份有限公司（以下简称"公司"）财务部门初步 测算： （1）预计 2025 年年度营业收入为 119,245.48 万元至 137,132.31 万元，与上 年同期相比，增加 11,398.10 万元至 29,284.93 万元，同比增长 10.57%到 27.15%。 （2）预计 2025 年利润总额为 19,578.57 万元至 23,494.28 万元，与上年同期 相比，增加 1,979.84 万元至 5,895.55 万元，同比增长 11.25%到 33.50%。 （3）预计 2025 年年度实现归属于母公司所有者的净利润为 19,105.21 万元 至 22,926.25 ...

格隆汇1月16日｜阳光诺和公告，公司预计2025年年度营业收入为119,245.48万元至137,132.31万元，与 上年同期相比，增加11,398.10万元至29,284.93万元，同比增长10.57%到27.15%。预计2025年利润总额 为19,578.57万元至23,494.28万元，与上年同期相比，增加1,979.84万元至5,895.55万元，同比增长 11.25%到33.50%。预计2025年年度实现归属于母公司所有者的净利润为19,105.21万元至22,926.25万 元，与上年同期相比，增加1,364.26万元至5,185.30万元，同比增长7.69%到29.23%。 ...

（文章来源：证券日报） 证券日报网讯 1月16日，阳光诺和在互动平台回答投资者提问时表示，STC008注射液的核心适应症为 肿瘤恶液质，该适应症覆盖多种癌症类型引发的恶液质状态，并非仅局限于非小细胞肺癌。公司此前披 露的 STC008 国内BD协议中提及"非小细胞肺癌的恶液质"，系基于合作阶段的临床研发聚焦方向，目 前该产品正针对肿瘤恶液质开展 I 期临床试验，初步探索其在恶液质患者中的安全性与初步有效性，未 限定特定癌种。关于其他癌症类型恶液质的拓展，公司将在现有临床研究数据的基础上，结合临床需 求、研究进展及监管要求，审慎评估向多癌种恶液质拓展的可行性。 ...

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

（文章来源：证券日报） 证券日报网讯 1月9日，阳光诺和在互动平台回答投资者提问时表示，STC007注射液针对术后疼痛的临 床试验正在按既定方案稳步推进，目前各项临床工作有序开展，相关进展符合预期。关于上市申请时 间，需根据临床试验数据结果、统计分析及注册申报准备情况综合确定，公司将根据法律法规要求及时 履行信息披露义务。市场竞争格局方面，目前国内术后疼痛治疗领域以传统镇痛药物为主，STC007以 kappa阿片受体（KOR）为靶点，强亲水性不易透过血脑屏障，可显著降低呼吸抑制、成瘾性等中枢系 统副作用，且镇痛持续时间更长，非精麻类处方便于临床使用，具有独特的作用机制与安全性优势，可 满足临床未被满足的需求。目前同靶点仅一家产品上市且已被纳入医保目录，后续公司将持续关注行业 竞争动态，聚焦产品临床价值与商业化落地，相关竞争信息以公开行业报告及公司公告为准。 ...